Vista Pharmaceuticals accepted the resignation of Mrs. Barkha Jain as Company Secretary and Compliance Officer effective September 4, 2026. The Board of Directors noted her communication and appreciated her services during her tenure.

Mrs. Jain tendered her resignation to pursue an alternate career opportunity outside the organisation. Her departure marks a change in key managerial personnel for the Hyderabad-based pharmaceutical firm.

Regulatory Disclosure

The company filed the disclosure pursuant to Regulation 30(2) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was submitted to BSE Limited on September 12, 2026.

The disclosure aligns with Para A of Part A of Schedule III to the regulations and Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026.

Key Details

Dhananjaya Alli, Executive Director, signed the intimation letter addressed to the stock exchange. The Board requested the company to file necessary forms with the Registrar of Companies and Ministry of Corporate Affairs.

Vista Pharmaceuticals Limited reported a net loss of ₹98.59 lakh for the quarter ended June 30, 2026, narrowing from a net loss of ₹129.04 lakh in the corresponding period of the previous year. The company recorded nil revenue from operations for the quarter, a significant decline from ₹151.88 lakh in Q1FY25.

The Hyderabad-based pharmaceutical manufacturer disclosed severe liquidity constraints during the period. Its credit facilities were classified as Non-Performing Assets (NPA) by lenders following a default in debt servicing for over 90 days. This classification resulted in a freeze on all working capital accounts, temporarily constraining operational liquidity.

Financial Performance

Total income for the quarter stood at ₹3.99 lakh, derived entirely from other income, as operational revenue remained at zero. Total expenses amounted to ₹136.70 lakh, driven primarily by employee benefits of ₹51.15 lakh and finance costs of ₹33.59 lakh.

The loss before tax narrowed to ₹132.71 lakh from ₹148.01 lakh in Q1FY25. Deferred tax credits of ₹34.12 lakh reduced the final net loss position. Basic earnings per share (EPS) were negative ₹0.16, compared to negative ₹0.22 in the prior year quarter.

Going Concern & Liquidity Risks

The company’s auditors highlighted a material uncertainty that may cast significant doubt on Vista Pharmaceuticals’ ability to continue as a going concern. Current liabilities exceeded current assets by ₹183.32 lakh as of June 30, 2026, reflecting negative working capital. The company has incurred cash losses for six consecutive years.

Management stated it is actively negotiating debt restructuring with lenders and implementing cost-rationalisation measures. To support operations, the company has secured a formal financial undertaking from subscribers of convertible share warrants to pay call money amounting to ₹922.49 lakh. The company has issued 10,249,998 convertible share warrants and received an upfront subscription of ₹307.50 lakh, with the balance due before September 19, 2026.

Statutory Liabilities & Compliance

Vista Pharmaceuticals disclosed outstanding statutory liabilities totaling approximately ₹44.68 lakh as of the quarter end. These include:

• Provident Fund payable: ₹33.15 lakh
• Tax Deducted at Source (TDS) payable: ₹7.16 lakh
• Employees' State Insurance payable: ₹2.44 lakh
• Professional Tax payable: ₹1.93 lakh

The delay in payments is attributed to working capital management challenges, with no pending disputes with statutory authorities. The unaudited financial results were reviewed by A.M Reddy & D.R Reddy, Chartered Accountants, and approved by the Board of Directors on August 14, 2026.